Oxidative Stress, Trace and Toxic Metal Levels In Alzheimer’S Disease In Sub-Sahara Africa

ISHIAQ Olayinka OMOTOSHO (ishiaqomotosh@yahoo.co.uk)
University of Ibadan College of Medicine

Michael Roland Ngwube
University of Ibadan

Jibril Omuya ABDUMALIK
University of Ibadan

Research article

Keywords: Alzheimer’s disease, oxidative stress, trace and toxic metal

DOI: https://doi.org/10.21203/rs.3.rs-38308/v1

License: ☒ This work is licensed under a Creative Commons Attribution 4.0 International License.
Read Full License
Abstract

Background

Alzheimer’s disease (AD), an age-related neurodegenerative disease characterized by loss of memory has been attributed to oxidative stress induced by accumulation of Amyloid (Aβ) protein in the brain; environmental and genetic alterations have been implicated as the pathogenesis of the disease. This work investigated levels of selected trace (Iron, Zinc and Copper) and toxic (Cadmium and Lead) metals in AD patients.

Method

In this case-control study, a total of 38 participants (aged ≥ 60 years) consisting of 18 clinically diagnosed AD subjects and 20 apparently healthy age-matched adults were recruited from the University College Hospital Ibadan Geriatric Centre. Semi-structured questionnaire was used to obtain demographic information, clinical history, lifestyle and dietary patterns from participants. Blood levels of iron, copper, zinc, lead and cadmium were analyzed using Atomic Absorption Spectrophotometry (AAS); levels of malondialdehyde (MDA), total antioxidant capacity (TAC), hydrogen peroxide (H₂O₂), and total plasma peroxide (TPP) were determined spectrophotometrically, while oxidative stress index (OSI) and copper to zinc ratio (Cu:Zn) were calculated.

Results

Mean plasma level of zinc was significantly lower in cases (86.04 ± 11.07 µg/dl) compared to controls (108.80 ± 12.47 µg/dl), while blood lead (13.85 ± 2.96 µg/dl, 8.32 ± 2.10 µg/dl) and cadmium (1.34 ± 0.71 µg/L, 0.71 ± 0.14 µg/L) levels were significantly higher in cases than in controls respectively. Although Fe and Cu levels were similar in cases and controls, Cu:Zn ratio was significantly elevated in cases compared to controls (p = 0.000). Though other OS markers were not significantly different in both groups, TPP was significantly higher in cases (64.96 ± 7.20 µmol/H₂O₂ vs. 55.41 ± 2.38 µmol/H₂O₂) while MDA correlated inversely with TAC in cases (r= −0.477, p = 0.045).

Discussion

The low plasma Zn coupled with high blood Pb and Cd levels may precipitate the elevated TPP and Cu:Zn ratio in cases. The reduced metallothioneine defense of the system as indicated by the elevated Cu:Zn ratio in cases may also exacerbate this problem.

Conclusion

The damaging effect of increasing toxic metal levels may be accentuating development of oxidative stress facilitating the progression of AD.

Background
The prevalence of age-related health problems is becoming an important public health concern as proportions of older individuals in populations worldwide grow (1). Alzheimer's disease (AD) is one of the most common age-related neurodegenerative diseases characterized by accumulation of a type of protein and its interplay with both environmental and genetic influences on the brain. Recently in 2013, studies by the Institute for health metrics and evaluation (2) showed that of all causes of death, AD was ranked fifth among most years of life lost in developed countries. A global study on neurodegenerative diseases estimated that Alzheimer's and other dementias were responsible for about 3% of all deaths in 2013. The largest relative increases were seen mainly in developing regions such as Sub-Saharan Africa (Niger, Eritrea etc.) where greater than 200% increases were recorded between 1990 and 2013 (2). Owing to the complex and diffuse etiology of the disease, considerable effort has been directed towards identification of an effective strategy to not only manage but also prevent these devastating brain pathologies. Although oxidative stress remains a major player in the pathogenesis of AD, diagnosis and management of the disease remain a medical challenge especially in terms of relating causes to effects.

Oxidative stress is essentially a result of imbalance in oxidant/antioxidant equation in the body, the high oxygen demand of the brain makes it vulnerable to oxidative damage by ROS (3). The role of oxidative stress in neurodegeneration is well documented. AD is characterized by abnormal protein deposition in the brain, and the typical hallmark in most neurodegenerative disorders such as AD and Parkinson's Disease (PD) is the interactions of these proteins with free radicals and metal ions leading to their increased aggregation and oxidative damage (4). Besides abnormal protein deposition, the lipid bilayer of the membrane is rich in polyunsaturated fatty acids and oxygen; it is therefore highly susceptible to lipid peroxidation leading to the generation of unstable end products, including aldehydes, such as malondialdehyde (MDA) (5). MDA is not only a product of oxidative damage to membrane lipids, it also drives the generation of oxidative stress by interfering with the antioxidant defense system. Some toxic trace metals (including Pb, Cd) have been reported to either facilitate production of oxidants by their toxicity (7, 8) while some essential metals (including Fe, Se and Cu) may also become prooxidants when present in excess amount in the body (9, 10).

Results of several researches have provided evidence that toxic metals can interact with DNA and proteins causing oxidative deterioration of biological macromolecules. Thus, the process of breakdown of metal-ion homeostasis has been reported in a plethora of diseases including neurological disorders (11, 12, 13).

Aside from generation of oxidants and ROS mediated by metal toxicity, the pathological hallmarks of AD include secretion/production of extracellular amyloid plaques and intracellular aggregates (neurofibrillary tangles). The major component of the amyloid plaques is the amyloid peptide Aβ, which results from the proteolysis of the amyloid precursor protein (APP). APP is an ubiquitously expressed transmembrane protein exerting a critical role in neuronal growth and survival (14, 15). The crucial factor in Aβ toxicity in the pathogenesis of AD has been linked with the idea, that Aβ peptide can form free radicals through the generation of hydrogen peroxide (13). This characteristic of Aβ is likely to derive mostly from its ability to bind metals and consequently, to mediate redox reactions (16, 17). In fact, Aβ1–42 has been reported as
a metallo-binding peptide with binding sites for Zn\(^{2+}\), Cu\(^{2+}\) and Fe\(^{3+}\) (18). The central tenet of A\(\beta\) toxicity is linked with the presence of redox metals, mainly copper and non-redox zinc (19, 13). Thus, the oxidative damage of A\(\beta\) is directly linked with the presence of redox metals, copper, and iron. A\(\beta\) has unusual high affinity for both transition metal ions- copper and iron- and has the capacity to reduce both metals and subsequently produce hydrogen peroxide and oxidized amyloid. This interplay between metals and oxidants in one hand with synthesis of A\(\beta\) protein is the ultimate focus of this work.

Methods

Recruitment of participants:

A total of 38 participants consisting of 18 patients clinically diagnosed with AD were recruited as cases, while 20 age-matched adults without clinical manifestation of any neurological disorder were recruited as controls. Participants, aged \(\geq\) 60 years (cases and controls) were recruited from the University College Hospital Geriatric Centre, Ibadan. Diagnosis was made using the National Institute of Neurological and Communicative Diseases and Stroke based on Alzheimer's disease and Related Disorders Association (NINCDS-ADRDA) diagnostic criteria for Alzheimer's dementia. INFORMED WRITTEN CONSENT FORM WAS DULY FILLED AND SIGNED BY EACH PARTICIPANT AFTER FULL EXPLANATION EVEN IN THEIR LOCAL LANGUAGE. Consenting adults above 60 years of age without any history of AD, Parkinson's disease, amyotrophic lateral sclerosis, schizophrenia or bipolar disorder were recruited as control.

Collection of Socio-demographic, anthropometric characteristics and clinical features of study participants

A structured questionnaire was used to obtain information on diet/lifestyle factors and other demographic and anthropometric indices like age, body weight, height, educational status, duration of AD, medical history, residential information and family history of participants.

Collection of Blood samples for biochemical indices:

Blood samples were collected from all participants for the determination of Essential trace elements (plasma Fe, Se and Cu) and toxic (blood Cd and Pb) metals, as well as for the estimation of plasma levels of malondialdehyde (MDA), total antioxidant capacity (TAC), hydrogen peroxide (\(\text{H}_2\text{O}_2\)), and total plasma peroxide (TPP).

LABORATORY METHODS AND PROCEDURES

Determination of total antioxidant capacity:

Total antioxidant capacity was estimated using the principle of Ferric Reducing Antioxidant Power (FRAP) as described by Benzie and Strain (20).

Determination of total plasma peroxide:
Total plasma peroxide levels were determined using the ferrous oxidation (FOX2) method (21) with minor modifications (22).

**Determination of malondialdehyde**

Estimation of MDA was carried out using the method of Adam-Vizi and Sergi (23).

**Determination of oxidative stress index:**

Oxidative stress index, an indicator of the degree of oxidative stress, was calculated from the above results as the percentage of total plasma peroxide (TPP) to total antioxidant capacity (TAC) values using the method of Harma et al., 2003 (24).

\[
\text{OSI (in %)} = \left[ \frac{\text{TPP (\mu mol H}_2\text{O}_2)/\text{TAC (\mu mol/L)}}{100} \right]
\]

**ESTIMATION OF TRACE METALS**

Essential trace metals (Iron, Zinc and Copper) and toxic metals (Cadmium and Lead) were measured using Atomic Absorption Spectrophotometry (AAS) using Perkin Elmer Analytic Atomic Absorption Spectrophotometer.

All the above laboratory procedures were performed following standard laboratory practices incorporating appropriate standards and controls

**STATISTICAL ANALYSIS**

Statistical Analysis was done using the statistical software package for social sciences (SPSS) version 20. Data were subjected to Shapiro Wilk's test for normality prior to analysis. Quantitative variables were expressed as mean ± standard deviation (SD) and categorical variables as percentages. Independent samples t-test (two-tailed) was used to compare the means of the quantitative variables, while Chi-Square test was used to test for association between categorical variables. Pearson's correlation was used to determine the degree of relationship between variables. Level of statistical significance was set at \( p<0.05 \).

**Results**

**Levels Of Trace Metals In Cases And Controls**

Table 1.0 shows the comparison of mean levels of trace metals analyzed in cases and controls. The mean plasma levels of Copper (116.90 ± 19.67; 118.41 ± 11.72) and Iron (134.89 ± 22.69; 140.09 ± 23.22) were not significantly different between cases and controls (\( p = 0.80; p = 0.49 \)) respectively. However, mean plasma Zinc level of 86.04 ± 11.07 µg/dL observed in cases was significantly lower than that of the controls, 108.80 ± 12.47 µg/dL (\( p = 0.000 \)). Mean blood lead (13.85 ± 2.96 µg/dL and 8.32 ± 2.10 µg/dL)
and mean cadmium levels (1.34 ± 0.71 µg/L and 0.71 ± 0.14 µg/L) were significantly higher in cases than in controls (p = 0.000, p = 0.000) respectively.

To evaluate the metallothionine capability of the system, the copper to zinc ratio (Cu:Zn) was calculated; this was found to be significantly higher in cases than in controls (p = 0.000).

### Table 1.0

Comparison of mean levels of trace metals in AD group and controls.

| Variable | Cases          | Controls        | t-test value | P-value |
|----------|----------------|-----------------|--------------|---------|
| Fe (µg/dL) | 134.89 ± 22.69 | 140.09 ± 23.22  | -0.697       | 0.490   |
| Cu (µg/dL) | 116.90 ± 19.67 | 118.41 ± 16.72  | -0.255       | 0.800   |
| Zn (µg/dL)  | 86.04 ± 11.07  | 108.80 ± 12.47  | -5.924       | 0.000*  |
| Pb (µg/dL)  | 13.85 ± 2.96   | 8.32 ± 2.10     | 6.696        | 0.000*  |
| Cd (µg/L)   | 1.34 ± 0.71    | 0.71 ± 0.14     | 3.905        | 0.000*  |
| Cu:Zn       | 1.36 ± 0.13    | 1.09 ± 0.16     | 5.520        | 0.000*  |

* Significant at p < 0.05. t = independent samples 't' test statistic

Legend/key: Fe = iron; Cu = copper; Zn = zinc; Pb = lead; Cd = cadmium

Table 2: Values of the various biochemical parameters were correlated using Pearson’s method. OSI index value strongly correlated negatively with the TAC value, a strong indication of relevance of oxidative stress in AD.

Cu and Fe also correlated absolutely while strong correlations were also observed between Zn and Cu in one hand and Zn and Fe on the other. The relative importance of Zn for the various metabolic processes of Fe and Cu along with their interrelationship especially the production of metallothionenien may be suggested by these findings.
Table 2
Pearson’s Correlation matrix on oxidative stress parameters and trace metals in cases

| Variables | MDA (r) | TPP (r) | TAC (r) | OSI (r) | Fe (r) | Cu (r) | Zn (r) | Pb (r) | Cd (r) |
|-----------|---------|---------|---------|---------|--------|--------|--------|--------|--------|
| MDA       | 1       |         |         |         |        |        |        |        |        |
| TPP       | -0.094  | 1       |         |         |        |        |        |        |        |
| TAC       | -0.477* | 0.222   | 1       |         |        |        |        |        |        |
| OSI       | 0.434   | 0.062   | -0.933**| 1       |        |        |        |        |        |
| Fe        | -0.252  | 0.059   | 0.000   | 0.039   | 1      |        |        |        |        |
| Cu        | -0.252  | 0.059   | 0.000   | 0.039   | 1.000**| 1      |        |        |        |
| Zn        | -0.169  | 0.128   | -0.103  | 0.132   | 0.834**| 0.834**| 1      |        |        |
| Pb        | -0.199  | 0.098   | -0.094  | 0.157   | 0.196  | 0.196  | 0.414  | 1      |        |
| Cd        | -0.139  | 0.173   | 0.027   | -0.020  | 0.112  | 0.112  | 0.021  | -0.312 | 1      |

* Correlation is significant at the 0.05 level (2-tailed).

** Correlation is significant at the 0.01 level (2-tailed).

Legend: MDA = Malonyldealdehyde; TPP = Total plasma peroxide; TAC = Total antioxidant capacity; OSI = Oxidative stress index, r = Pearson’s correlation coefficient.

Discussion

Alzheimer’s disease (AD) remains the leading cause of dementia in the older population, and stands as the fourth highest cause of disability and death in the elderly (25). One of the major clinical features of AD is the chronic decline in cognitive function and overall poor daily living. Cognition, a major clinical feature of AD, has been linked with the delicate balance in the biochemical milieu of neurons, which is also related to neuronal oxidant/antioxidant balance (26). This study investigated the relationship between oxidant/antioxidant levels and some environmental trace and toxic metals reported to impact on the maintenance of this oxidative balance; the possible contribution of trace and toxic metals in the pathogenesis of several neurodegenerative conditions including AD in this environment was therefore examined.

Zn is one of the essential trace metals that modulate oxidative damage activities in the body. In the brain, metallothionein, the active antioxide form of Zn, is expressed as MT-3, and is a key antioxidant in the blood-brain barrier capable of binding to and preventing brain exposure to cadmium, mercury, arsenic, copper and other toxic metals. There have been several reports on the contribution of trace metals in the generation and neutralization of ROS in-vivo (27).
In this study, plasma zinc levels in AD were significantly lower than that of controls; this corroborates the findings in different studies (28, 29). The brain has been reported to be second only to the beta cells of the pancreas to contain the highest concentration of zinc (30), where it performs diverse roles in key processes such as enzymatic activity, neurotransmitter release and modulation of gated ion channels for synaptic transmission (31). However, different studies have reported the antagonistic role of Aβ protein, an established macromolecule known to facilitate the development of AD by accumulating zinc ions in different studies on AD making Zn unavailable to protect the neurons through the formation of metallothionein complex (32, 33). Hence, the low zinc levels in this study may therefore be attributed to the zinc binding ability of the Aβ protein abundant in AD subjects. In normal physiology, zinc is released from the neocortical glutameric synapse which is readily exchangeable with plasma zinc pool (34). Mechanistically, as Aβ in AD brains continue to trap and accumulate zinc in these synapses, it creates a gradient that favors movement of zinc into the synaptic pool which in turn depletes zinc from the plasma zinc pool. This is supported by the findings of (35), where low plasma levels of zinc in AD patients returned to normal levels after treatment with zinc binding compound, Clioquinol, which also have Aβ disintegrating properties.

Also, zinc deficiency has been associated with increased levels of oxidative damage including increased lipid, protein and DNA oxidation (36). Hence, as an antioxidant, zinc at physiologic concentrations protects the body’s sulfhydryl pool directly by antagonizing other redox active metals (e.g. copper) or indirectly by serving as a cofactor for key antioxidant enzymes such as Cu/Zn-SOD (36). Although an equivocal relationship of Zn in the development of AD as reflected by its non-significant relationship with OS markers was seen in this study, this may be more in consonance with previous works that questioned the link between this micronutrient and the development of AD (30). It may also be attributed to strict compensatory mechanisms of the body that always maintain serum concentrations of trace essential metals such as copper and zinc at a given physiological ratio often expressed as copper:zinc ratio (Cu:Zn) (37). Hence, the expression of copper as a ratio to zinc towards establishing the interplay of the two micronutrients in OS pathogenesis of AD becomes important. Previous work showed evidence that an increase in Cu:Zn was associated with several chronic age-related diseases (38) and systemic OS (39). Thus the observed significantly increased Cu:Zn in AD patients in comparison to controls in this study may be worthy of note. Elevated Cu:Zn has been associated with mortality in the elderly and reflects an inflammatory response (38). Since Zn is an important element that maintains the level of metallothionein which has been severally established as a major antioxidant in the brain, a reduction in its level especially in the presence of an increase in levels of Cu and Fe may facilitate the oxidant tendencies of Cu and Fe. This may therefore largely explain the progression of AD especially with respect to increase in cognitive dysfunction. This may then be exacerbated by several other mechanisms during inflammatory conditions driving an increase in plasma concentration of copper at the expense of zinc as reported by other severally (40).

Discussions on the role of iron and copper in the pathogenesis of AD may be said to be interrelated. Studies on iron and copper in AD have shown that excess of both metals stimulates hydroxyl radical formation via the Fenton reaction, which may contribute to increased OS in AD (41). Though in this study,
plasma copper levels were not significantly different in both groups, reports on the role of copper in AD pathogenesis remain largely equivocal (42, 43, 44). Also, the non-significant difference in plasma iron levels in cases and controls as seen in this study is similar to results of some meta-analyses which reported unchanged or reduced plasma iron levels in AD patients compared to controls (45, 46). Notwithstanding, the increase in Cu:Zn ratio observed may largely precipitate the toxicity of both Cu and Fe especially in advanced age as seen in participants in this study.

Lead in biological systems is a neurotoxicant and a risk factor for neurodegenerative diseases (47). The significantly elevated blood lead levels (BLL) observed in AD patients in this study was consistent with findings of a similar study (48). Environmental exposure to pollutants has been reported as veritable source of Lead contamination (49); hence, the elevated BLL observed in AD patients in this study may be attributed to the higher proportion of AD patients living in low-income residential areas/slums (88.9%) and/or with houses closer to tarred roads (50%) than in the controls. Previous works also observed that exposure to leaded gasoline in persons living near major roads was associated with an increased incidence of dementia (also a known age related neurodegenerative disease) (50).

Leaded gasoline is one of the possible sources of environmental lead exposure. This is quite veritable in Nigeria with an average lead content of 0.66 g/L of gasoline in the country (51, 49). This, in conjunction with the high proportion of poorly maintained second hand vehicles common in Nigerian cities (49), may contribute significantly to environmental pollution via release of large quantities of incompletely combusted hydrocarbons in exhaust fumes, which release high percentage of lead into the atmosphere (52). This is further supported by the evidence that distance from roadways has been found to be inversely correlated with soil lead concentrations and human BLL (53, 54). Vocational engagement has also been linked to the development of neurodegenerative diseases; a significant proportion of the AD patients (61.1%) were found to be engaged in unskilled labor, which has also been associated with an increased risk of exposure to toxic metals (Ji et al., 2014) (55).

That elevated blood cadmium levels as observed in this study may predispose subjects to AD has also been previously reported (56). This is further supported by a larger scale study conducted on a US-based population (57). Since mode of exposure of cadmium in human is similar to that of Lead, engagement in unskilled labor and living in low-income, traffic prone areas may be the plausible link between elevated blood cadmium levels and AD in this study. Previous work also reported that road traffic associated emissions of metals such as cadmium from vehicle parts (such as tyres and brake linings) remain major sources of exposure to Cd in environmental pollution (58).

However, the level of blood cadmium in AD patients in this study was much higher than that observed (1.34 ± 0.71 ug/L vs. ~0.6ug/L). Orisakwe, in a review (59), argued that Nigeria like most developing nations, is awash with heavy metals. This is backed by findings in environmental studies conducted in different parts of the country (49, 61, 62).

In this study engaging in unskilled labor, living in local residential areas/slums or closer to tarred roads were mostly associated with AD. A significant association between menial low skill occupations and AD
dementia has been previously reported (63) while traffic-related air pollution has been reported to be associated with increased risk of developing AD dementia (Hazard Ratio = 1.6) (64).

Though genetics is one of the major risk factors for developing many neurological diseases, AD was not associated with family history of the disease in this study. This may indicate that the development of AD in this environment is either sporadic or may have been previously overlooked by families of affected individuals as part of the normal ageing process. In conclusion, oxidative stress may be linked as the pathogenesis of AD in participants as seen from results of this study, this might have been precipitated by the residential and vocational dispositions. However, the progression of the disease may largely be due to an increase in the Cu:Zn ratio making the brain more vulnerable to the damaging effect of the antioxidants accumulating in the process.

**Conclusion**

AD has been known to be associated with accumulation of oxidants with its deleterious effect especially in the brain. However, progression of this disease is accentuated by an imbalance in levels of essential elements some of which may become pro-oxidants thus increasing the pool of oxidants and thereby accentuating progression of the disease. Environmental factors may also be playing significant role in the development of essential metal imbalance with its attendant problems. In this study, genetic manipulation may not be playing a significant role in AD development in spite of its prevalence while the low awareness of the disease may be due to the level of public health knowledge.

**Abbreviations**

AAS Atomic Absorption Spectrometry

AD Alzheimer's Disease

APP Amyloid beta Precursor Protein

Aβ Amyloid Beta

BLL Blood Lead Levels

Cd Cadmium

Cu Copper

Cu:Zn Copper to Zinc ratio

DNA Deoxyribonucleic Acid

Fe Iron
Declarations

Ethics approval and consent to participate:
Approval was obtained from the University of Ibadan/University College Hospital joint ethics committee. (Approval No: UI/EC/18/0152)

Consent for publication:
All authors agreed that the manuscript be published in BMC

Availability of data and materials:
Materials and data in this manuscript can be made available to the public

Competing interests:
There are no competing interests between authors and with any other party

Funding:
This work was personally funded by the 3 authors, no external funding or grant was used in executing the project.

Authors' contributions:
1st Author designed, supervised the work and wrote the manuscript; 2nd author carried out the laboratory analysis including statistical analysis of the results; 3rd author carried out the clinical aspects of the work, recruited participants and reviewed the manuscript.

Acknowledgements:

The cooperation of various participants in the execution of this work both in the clinic, the analytical laboratory and also from all laboratory staff that assisted in the work is hereby acknowledged.

References

1. World Health Organization, 2008. The world health report: primary health care now more than ever. Geneva.
2. Institute for health metrics and evaluation (IHME), 2014. A closer look at Alzheimer's disease worldwide. IHME IMPACT ISSUE.
3. Su, B., Wang, X., Nunomura, A., et al. 2008. Oxidative stress signaling in Alzheimer's disease. Current Alzheimer Research, 5:6; 525–532.
4. Alessandra, G. and Robert, C. H. 2005. The crucial role of metal ions in neurodegeneration: the basis for a promising therapeutic strategy. British Journal of Pharmacology, 146(8): 1041–1059.
5. Uchida, K. 2003. 4-Hydroxy-2-nonenal: A product and mediator of oxidative stress. Progress in Lipid Research. 42: 4; 318-343.
6. Shakila T., Wang H-J., Carey J., Banks W., and Ercal N., 2014. Effects of Lead and Cadmium on brain endothelial cell survival, monolayer permeability, and crucial oxidative stress markers in an in Vitro model of the blood-brain barrier, Toxics, 2(2), 258-275.
7. Patra, R. C., Rautray, A. K., & Swarup, D. (2011). Oxidative Stress in Lead and Cadmium Toxicity and Its Amelioration. Veterinary Medicine International, 1–9.
8. Forester S.C. and Lambert J.D., 2011. The role of antioxidant versus pro-oxidant effects of green tea polyphenols in cancer prevention. Molecular Nutrition & Food Research, 55(6), 844-854.
9. Irshad M. and Chaudhuri P.S., 2002. Oxidant-antioxidant system: Role and significance in human body. Indian journal of Experimental Biology, 40, 1233-1239.
10. Halliwell, B. and Gutteridge, J. M. C., 2007. Free radicals in Biology and Medicine, 4th edition Oxford University Press.
11. Mates, J. M. 2000. Effects of antioxidant enzymes in the molecular control of reactive oxygen species toxicology. Toxicology, 153: 83-104.
12. Valko, M., Morris, H. and Cronin, M. T. D. 2005. Metals, toxicity and oxidative stress. Current Medicinal Chemistry. 11:1161–1208.
13. Turner, P. R., O’Connor, K., Tate, W. P. and Abraham, W. C. 2003. Roles of amyloid precursor protein and its fragments in regulating neural activity, plasticity and memory. Progress in Neurobiology. 70;
1-32.
14. Priller, C., Bauer, T., Mitteregger, G., Krebs, B., Kretzschmar, H.A. and Herms, J. 2006. Synapse formation and function is modulated by the amyloid precursor protein. *Journal of Neuroscience*. 26, 7212-7221.
15. Valko, M., Morris, H. and Cronin, M. T. D. 2005. Metals, toxicity and oxidative stress. *Current Medicinal Chemistry*. 11:1161–1208.
16. Butterfield, D. A. and Kanski J. 2002. Methionine residue 35 is critical for the oxidative stress and neurotoxic properties of Alzheimer's amyloid beta-peptide 1–42. *Peptides*, 23:1299–1309.
17. Butterfield D. A., Drake J., Pocernich C. and Castegna A. 2001. Evidence of oxidative damage in Alzheimer's disease brain: central role for amyloid beta-peptide. *Trends in Molecular Medicine*, 7:548-554.
18. Huang, X., Atwood, C. S., Hartshorn, M. A., Multhaup, G., Goldstein, L. E., Scarpa R. C., et al. (1999). The A beta peptide of Alzheimer's disease directly produces hydrogen peroxide through metal ion reduction. *Biochemistry* 38:7609-7616.
19. Bush, A.I., Curtain, C.C., 2008. Twenty years of metallo-neurobiology: where to now? *European Biophysics Journal with Biophysics Letters*, 37: 241–245.
20. Benzie I.F and Strain J.J., 1999. Ferric reducing/antioxidant power assay: direct measure of total antioxidant activity of biological fluids and modified version for simultaneous measurement of total antioxidant power and ascorbic acid concentration. *Methods in Enzymology*, 299, 15-27.
21. Miyazawa T., 1989. Determination of phospholipid hydroperoxides in human blood plasma by a chemiluminescence-HPLC assay. *Free Radical Biology and Medicine*, 7(2), 209-218.
22. Harma M, Harma M and Erel O. 2005. Measurement of the total antioxidant response in preeclampsia with a novel automated method. *European Journal of Obstetrics & Gynecology and Reproductive Biology*, 10: 47-51.
23. Adam-Vizi V. and Sergi A., 1982. Receptor independent stimulatory effect of noradrenaline on NA, K-ATPase in rat brain homogenate: Role of Lipid peroxidation. *Biochemical Pharmacology*, 31(13), 2231-2236.
24. Harma M. Harma M. Enel O (2003). Increased oxidative stress in patients with hydatidiform mole. *Swiss Medical Weekly*. 133:563-566.
25. Yuan, Y., Niu, F., Liu, Y. and Lu, N. 2014. Zinc and its effects on oxidative stress in Alzheimer's disease. *Neurological Sciences*, 35(6): 923–928.
26. Massaad, C. A. and Klann, E. 2011. Reactive oxygen species in the regulation of synaptic plasticity and memory. *Antioxidants and redox signaling*, 14(10): 2013-54.
27. Jomova, K., and Valko, M., 2011. Advances in metal-induced oxidative stress and human disease. *Toxicology*, 283(2-3): 65–87.
28. Guan, C., Dang, R., Cui, Y., Liu, L., Chen, X., Wang, X., et al. 2017. Characterization of plasma metal profiles in Alzheimer's disease using multivariate statistical analysis. PLoS ONE 12(7): e0178271.
29. Pu, Z., Xu, W., Lin, Y., He, J. and Huang, M. 2017. Oxidative Stress Markers and Metal Ions are Correlated With Cognitive Function in Alzheimer’s Disease. *American Journal of Alzheimer’s Disease and Other Dementias*, 20: 10, 1-7.

30. Frazzini, V., Rockabrand, E., Mocchegiani, E. and Sensi, S. L. 2006. Oxidative stress and brain aging: is zinc the link? *Biogerontology*, 7(5-6): 307–314.

31. Barr, C. A. and Burdette, S. C. 2017. The zinc paradigm for metalloneurochemistry. *Essays in Biochemistry*, 61: 225–235.

32. Bush, A. I., Pettingell, W. H., Multhaup, G., d Paradis, M., and Vonsattel J. P. 1994. Rapid induction of Alzheimer A beta amyloid formation by zinc. *Science*, 265:1464–1467.

33. Liu, S., Howlett, G., and Barrow, J. C. 1999. Histidine-13 Is a Crucial Residue in the Zinc Ion-Induced Aggregation of the Aβ Peptide of Alzheimer’s Disease. *Biochemistry*, 38(29): 9373-9378.

34. Friedlich, A. L., Lee, J. Y., van Groen, T., Cherny, R. A., Volitakis, I., Cole, T. B., Palmiter, R. D., Koh, J. Y., and Bush, A. I. 2004. Neuronal zinc exchange with the blood vessel wall promotes cerebral amyloid angiopathy in an animal model of Alzheimer’s disease. *Journal of Neuroscience*, 24: 3453-3459.

35. Ritchie, C. W., Bush, A. I., Mackinnon, A., Macfarlane, S., Mastwyk, M., and MacGregor, L. 2003. Metal-protein attenuation with iodochlorhydroxyquin (clioquinol) targeting Abeta amyloid deposition and toxicity in Alzheimer disease: a pilot phase 2 clinical trial. *Archives of Neurology*. 60(12): 1685-1691.

36. Prasad, A.S., 2009. Zinc: role in immunity, oxidative stress and chronic inflammation. *Current Opinion in Clinical Nutrition and Metabolic Care*, 12: 646–652.

37. Osredkar, J. and Sustar, N. 2011. Copper and zinc, biological role and significance of copper/zinc imbalance. *Journal of Clinical Toxicology*, S3:001. doi: 10.4172/2161-0495.S3-001

38. Malavolta, M., Piacenza, F., Basso, A., Giacconi, R., Costarelli, L., and Mocchegiani, E. 2015. Serum copper to zinc ratio: Relationship with aging and health status. *Mechanisms of Ageing and Development*, 151, 93–100.

39. Mezzetti, A., Pierdomenico, S. D., Costantini, F., Romano, F., De Cesare, D., Cuccurullo, F. 1998. Copper/zinc ratio and systemic oxidant load: effect of aging and aging-related degenerative diseases. *Free Radical Biology and Medicine*, 25(6): 676–681.

40. Roberto Milanino 1, Mauro Marrella, Roberta Gasperini, Mara Pasqualicchio and Giampaolo Velo. Basel Copper and zinc body levels in inflammation: an overview of the data obtained from animal and human studies. Agents and Actions 39 (1993) 0065-4299/93/040195-15 $1.50+0.20/0 9 1993 Birkh/iuser Verlag.

41. Li, X., Lv, Y., Yu, S., Zhao, H. and Yao, L. 2012. The effect of cadmium on Abeta levels in APP/PS1 transgenic mice. *Experimental and Therapeutic Medicine*,4: 125–130.

42. Vaz F.N.C., Fermino B.L., Haskel M.V.L, Wouk J., de Freitas G.B.L., Fabbri R. Montagna E. Rocha J.B.T and Bonini J.S., 2017. The relationship between copper, iron, and selenium levels and Alzheimer disease. *Biological Trace Element Research*, 181(2), 185-191.

43. Lovell, M. A., Robertson, J. D., Teesdale, W. J., Campbell, J. L. and Markesbery, W. R. 1998. Copper, iron and zinc in Alzheimer's disease senile plaques. *Journal of Neurologic Science*, 158: 47–52.
44. Deibel M.A., Ehmann W.D. and Markesbery W.R., 1996. Copper, iron and zinc imbalances in severely degenerated brain regions in Alzheimer's disease: Possible relation to oxidative stress. *Journal of the Neurological Sciences*, 143, 137-142.

45. Tao, Y., Wang, Y., Rogers, J. T. and Wang, F. 2014. Perturbed iron distribution in Alzheimer's disease serum, cerebrospinal fluid, and selected brain regions: a systematic review and meta-analysis. *Journal of Alzheimer's Disease*, 42: 679–690.

46. Wang, Z. X., Tan, L., Wang, H. F., Ma, J., Liu, J., Tan, M. S., et al. 2015. Serum Iron, Zinc, and Copper levels in patients with Alzheimer's disease: a replication study and meta-analyses. *Journal of Alzheimer's Disease*, 47: 565–581.

47. Monnet-Tschudi, F., Zurich, M. G., Boschat. C., Corbaz, A. and Honegger, P. 2006. Involvement of environmental mercury and lead in the etiology of neurodegenerative diseases. *Reviews on Environmental Health*, 21(2): 105-118.

48. Fathabadi, B., Dehghanifiroozabadi, M., Aaseth, J., Sharifzadeh, G., Nakhaee, S., Rajabpour-Sanati, A., et al. 2018. Comparison of Blood Lead Levels in Patients With Alzheimer's Disease and Healthy People. *American Journal of Alzheimer's Disease & Other Dementias*, 153331751879403. doi:10.1177/1533317518794032

49. Orisakwe, O. E. 2009. Environmental Pollution and Blood Lead Levels in Nigeria: Who is Unexposed? *International Journal of Occupational and Environmental Health*, 15(3): 315–317.

50. Chen, H., Kwong, J. C., Copes, R., Tu, K., Villeneuve, P. J., van Donkelaar, A., et al. 2017. Living near major roads and the incidence of dementia, Parkinson's disease, and multiple sclerosis: a population-based cohort study. *The Lancet*, 389(10070): 718–726.

51. Fakayode, S. O. and Olu-Owolabi, B. I. 2003. Heavy metal contamination of roadside topsoil in Osogbo, Nigeria: its relationship to traffic density and proximity to highways. *Environmental Geology*, 44:150-157.

52. Baumbach, G., Vogt, U., Hein, K. R. G., et al. 1995. Air pollution in a large tropical city with high traffic density: results of measurements in Lagos, Nigeria. *Science of the Total Environment*, 169:25-31.

53. Shih, R. A., Hu, H., Weisskopf, M. G. and Schwartz, B. S. 2007. Cumulative lead dose and cognitive function in adults: a review of studies that measured both blood lead and bone lead. *Environmental Health Perspectives*, 115(3): 483-492.

54. Weisskopf, M. G., Wright, R. O., Schwartz J., et al. 2004. Cumulative lead exposure and prospective change in cognition among elderly men: the VA Normative Aging Study. *American Journal of Epidemiology*, 160(12): 1184-1193.

55. Ji, J. S., Schwartz, J., Sparrow, D., Hu, H. and Weisskopf, M. G. 2014. Occupational determinants of cumulative lead exposure: analysis of bone lead among men in the VA normative aging study. *Journal of occupational and environmental medicine*, 56(4): 435-40.

56. Basun, H., Forsell, L. G., Wetterberg, L. and Winblad, B. 1991. Metals and trace elements in plasma and cerebrospinal fluid in normal ageing and Alzheimer's disease. *Journal of Neural Transmission - Parkinson's Disease and Dementia Section*, 4: 231-258.
57. Min J. and Min K., 2016. Blood cadmium levels and Alzheimer's disease mortality risk in older US adults. *Environmental Health*, 15(1).

58. Hjortenkrans D. 2008. Road traffic metals – sources and emissions, Dissertation, University of Kalmar, Sweden, ISBN: 978-91-85993-07-9.

59. Orisakwe O.E., 2014. Lead and cadmium n public health in Nigeria: physicians neglect and pitfall in patient management. *North American Journal of Medical Sciences*, 6(2), 61.

60. Orisakwe O.E. and Nduka J.C., 2009. Effects of effluents from Warri refinery petrochemical company WRPC on water and soil qualities of “contiguous host” and “impacted on communities” of Delta State, Nigeria. *The Open Environmental Pollution & Toxicology Journal*, 1, 11-17.

61. Farombi E.O., Adelowo O.A., and Ajimoko Y.R., 2007. Biomarkers of oxidative stress and heavy metal levels as indicators of environmental pollution in African catfish (*Clarias gariepinus*) from Nigeria Ogun river. *International Journal of Environmental Research and Public Health*, 4(2), 158-165.

62. Abdullahi M.S., Uzaira A., Harrison G.F.S., and Balarabe M.L., 2007. Trace metals screening of tomatoes and onions from irrigated farmlands on the bank of River Challawa, Kano, Nigeria. *Electronic Journal of Environmental, Agricultural and Food Chemistry*, 6(3), 1870-1877.

63. Bonaiuto, S., Rocca, W. A., Lippi, A., Giannandrea, E., Mele, M., Cavarzeran, F., and Amaducci, L. 1995. Education and Occupation as Risk Factors for Dementia: A Population-Based Case-Control Study. *Neuroepidemiology*, 14(3): 101–109.

64. Oudin A., Forsberg B., Adolfsson A.N., Lind N., Modig L., Nordin M., and Nilsson L.G., 2015. Traffic-related air pollution and Dementia incidence in Northern Sweden: A longitudinal Study. *Environmental Health Perspectives*, 124(3), 306-312.